Search Results
Jim Cramer on how Eli Lilly could be impacted by mixed Alzheimer's drug study results
Jim Cramer on how Lilly's Alzheimer's drug compares to Biogen's
Eli Lilly Alzheimer’s drug could slow disease, but comes with side effects
Eli Lilly CEO: We see a path to an Alzheimer's disease-modifying drug
Eli Lilly CEO on FDA approval pathway for Alzheimer's drugs
Eli Lilly testing Alzheimer's drug
Jim Cramer: Eli Lilly stock represents real value
Eli Lilly conducts study on Alzheimer's treatment
Eli Lilly Alzheimers drug slows cognitive decline
Eli Lilly’s chief scientific officer on Covid antibody drug results
Eli Lilly CEO David Ricks on positive Alzheimer's drug trial data
New Alzheimer's drug leading to underwhelming results
